Ceregene, Inc. develops adeno-associated virus (AAV) gene therapies for the treatment of neurodegenerative disorders using the delivery of nervous system growth factors.  As of October 1, 2013, Ceregene, Inc. operates as a subsidiary of Sangamo Biosciences Inc.